Tonix Pharmaceuticals Highlights TNX-102 SL at Global Conference
The 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems recently brought together industry experts to explore the latest advancements in pharmaceutical formulations. Among the standout presentations was Tonix Pharmaceuticals Holding Corp., showcasing their innovative candidate, TNX-102 SL—a sublingual formulation of cyclobenzaprine HCl specifically designed for treating fibromyalgia.
Key Clinical Discoveries
During their talks, Tonix Pharmaceuticals revealed the proprietary technology and pharmacokinetic properties behind TNX-102 SL. The patents covering its composition and methods are expected to secure market exclusivity until 2034 in various regions around the globe. The company intends to file a New Drug Application (NDA) with the U.S. FDA by October 2024 and has received Fast Track designation to expedite the review process.
Encouraging Findings from Phase 3 Trials
The Phase 3 RESILIENT study provided strong evidence supporting TNX-102 SL’s effectiveness, showing a statistically significant improvement in alleviating fibromyalgia-related nociplastic pain, along with better sleep quality and overall patient well-being.
Insights from Notable Presentations
One presentation, spearheaded by Prof. Marino Nebuloni, focused on mannitol’s role as a eutectic forming agent, crucial for delivering cyclobenzaprine effectively via the sublingual route. This formulation guarantees a stable product that dissolves quickly into the bloodstream, thereby maximizing the intended therapeutic benefits.
Expert Perspective on Clinical Needs
Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, spoke about the pressing need for effective fibromyalgia treatments, expressing dissatisfaction with existing options. He highlighted TNX-102 SL's promise as a once-daily treatment that could signal a significant shift in fibromyalgia management.
Innovative Development of Dosage Forms
At the conference, Dr. Bruce Daugherty examined the pharmacokinetic properties of TNX-102 SL, focusing on its design to enhance absorption and effectiveness when taken at bedtime. This specialized formulation aims to help those struggling with sleep disturbances while minimizing unwanted daytime drowsiness.
Findings from Additional Research
Siobhan Fogarty also delivered a presentation emphasizing the role of in vitro discriminatory tests in the development of the TNX-102 SL tablet. These tests assess essential factors like dissolution and disintegration time, underscoring that consistent product quality is vital for achieving effective therapeutic results.
Tonix's Dedication to Medical Advancement
Tonix Pharmaceuticals is committed to improving treatment standards for fibromyalgia and other conditions, as evidenced by their diverse pipeline of investigational drugs. Their recent progress highlights not only the potential of TNX-102 SL but also the company's active approach to meeting unmet medical needs.
Frequently Asked Questions
What is TNX-102 SL?
TNX-102 SL is a sublingual formulation of cyclobenzaprine HCl created to treat fibromyalgia.
When is the NDA submission for TNX-102 SL planned?
The NDA submission is scheduled for October 2024.
What were the results of the Phase 3 RESILIENT study?
The study revealed significant improvements in managing fibromyalgia pain and enhancing sleep quality compared to a placebo.
How does TNX-102 SL differ from current fibromyalgia treatments?
TNX-102 SL is designed to offer a more effective once-daily treatment option with fewer daytime side effects.
Who is presenting the research on TNX-102 SL?
Notable presentations include insights from company executives and researchers, including Prof. Marino Nebuloni and Dr. Bruce Daugherty.
